Repetitive Transcranial Magnetic Stimulation for Treatment-resistant Depression: a Systematic Review and Meta-analysis
Overview
Authors
Affiliations
Objective: To evaluate the efficacy of repetitive transcranial magnetic stimulation (rTMS) in patients with major depressive disorder (MDD) and 2 or more prior antidepressant treatment failures (often referred to as treatment-resistant depression [TRD]). These patients are less likely to recover with medications alone and often consider nonpharmacologic treatments such as rTMS.
Data Sources: We searched MEDLINE, EMBASE, the Cochrane Library, PsycINFO, and the International Pharmaceutical Abstracts for studies comparing rTMS with a sham-controlled treatment in TRD patients ages 18 years or older.
Study Selection: We included 18 good- or fair-quality TRD studies published from January 1, 1980, through March 20, 2013.
Data Extraction: We abstracted relevant data, assessed each study's internal validity, and graded strength of evidence for change in depressive severity, response rates, and remission rates.
Results: rTMS was beneficial compared with sham for all outcomes. rTMS produced a greater decrease in depressive severity (high strength of evidence), averaging a clinically meaningful decrease on the Hamilton Depression Rating Scale (HDRS) of more than 4 points compared with sham (mean decrease = -4.53; 95% CI, -6.11 to -2.96). rTMS resulted in greater response rates (high strength of evidence); those receiving rTMS were more than 3 times as likely to respond as patients receiving sham (relative risk = 3.38; 95% CI, 2.24 to 5.10). Finally, rTMS was more likely to produce remission (moderate strength of evidence); patients receiving rTMS were more than 5 times as likely to achieve remission as those receiving sham (relative risk = 5.07; 95% CI, 2.50 to 10.30). Limited evidence and variable treatment parameters prevented conclusions about which specific treatment options are more effective than others. How long these benefits persist remains unclear.
Conclusions: For MDD patients with 2 or more antidepressant treatment failures, rTMS is a reasonable, effective consideration.
Ye S, Wang B, Sui H, Xiu M, Wu F Schizophrenia (Heidelb). 2025; 11(1):41.
PMID: 40064894 PMC: 11894214. DOI: 10.1038/s41537-025-00590-5.
Zhao M, Li Y, Zhao H, Jiang C, Huang M J Zhejiang Univ Sci B. 2025; 26(1):52-57.
PMID: 39815610 PMC: 11735914. DOI: 10.1631/jzus.B2300765.
Implications of Transcranial Magnetic Stimulation in Geriatric Patients With Pseudodementia.
Coats Z, Coats W Cureus. 2024; 16(11):e73981.
PMID: 39703285 PMC: 11656504. DOI: 10.7759/cureus.73981.
Nair A, Klimes-Dougan B, Silamongkol T, Basgoze Z, Roediger D, Mueller B J Affect Disord. 2024; 372:665-675.
PMID: 39701468 PMC: 11792619. DOI: 10.1016/j.jad.2024.12.057.
Ishikawa Y, Oishi N, Kyuragi Y, Hatakoshi M, Hirano J, Noda T Mol Psychiatry. 2024; .
PMID: 39681629 DOI: 10.1038/s41380-024-02874-1.